Catalyst Wire Dossier Catalyst Wire Dossier

Alvespimycin (KOS-1022)

alvespimycin
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Alvespimycin (KOS-1022), covering 2011-06-27 to 2011-06-27. Get the full timeline:

Most recent: Clinical Trial Update: Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy [Phase 1]

See pricing